Epigenetic Regulation

Overview

Epigenetic regulation refers to heritable and reversible control of gene expression without changing the underlying DNA sequence. Major mechanisms include DNA methylation (5-methylcytosine, 5-hydroxymethylcytosine), histone modifications (acetylation, methylation, phosphorylation, ubiquitination), chromatin remodeling complexes, and regulatory non-coding RNAs (miRNAs, siRNAs, lncRNAs, circRNAs).^{1Epigenetics in Neurodegenerative Diseases (2025)2025 · Subcellular Biochemistry · PMID 39820861Open reference2Epigenetics-Based Therapeutics for Neurodegenerative Disorders2012 · Current Translational Geriatrics and Experimental Gerontology Reports · PMID 23526405Open reference} In neurodegenerative diseases, epigenetic disruption alters neuronal identity programs, stress responses, inflammatory tone, proteostasis, and vulnerability to toxic protein accumulation.^{3DNA Methylation in Alzheimer's Disease2020 · Journal of Alzheimer's Disease · PMID 32754928Open reference4Epigenetics of Parkinson's Disease2018 · Cellular and Molecular Life Sciences · PMID 29588157Open reference}

Core Epigenetic Mechanisms

DNA Methylation

DNA methylation involves the addition of a methyl group to cytosine residues in CpG dinucleotides, typically resulting in gene silencing. 5-methylcytosine (5mC) can be oxidized to 5-hydroxymethylcytosine (5hmC), which is enriched in neurons and associated with active gene expression.^{55-Hydroxymethylcytosine in Brain Aging and Neurodegeneration2015 · Nature Reviews Neuroscience · PMID 26254279Open reference}

Key enzymes:

• DNA Methyltransferases (DNMTs): DNMT1 (maintenance), DNMT3A/3B (de novo)

• TET enzymes: TET1, TET2, TET3 (5mC → 5hmC → 5fC → 5caC)

Alzheimer’s disease:

• Global hypomethylation in brain tissue with gene-specific hypermethylation

• APP promoter hypomethylation increases Aβ production^{6APP Promoter Methylation and Alzheimer's Disease2011 · Journal of Alzheimer's Disease · PMID 21472023Open reference}

• MAPT promoter methylation altered in tauopathy

• 5hmC levels change with disease progression

Parkinson’s disease:

• SNCA promoter hypomethylation increases α-synuclein expression^{7SNCA Methylation and Parkinson's Disease2015 · Neurology · PMID 25540006Open reference}

• LRRK2 regulatory regions show altered methylation

• Global DNA methylation changes in substantia nigra

ALS/FTD:

• C9orf72 promoter hypermethylation reduces toxic hexanucleotide repeat expression (protective)^{8C9orf72 Promoter Methylation and ALS/FTD2013 · Neuron · PMID 23233530Open reference}

• SOD1, FUS regulatory regions affected

Histone Modifications

Histones undergo post-translational modifications that alter chromatin structure and gene expression.

Alzheimer’s disease:

• Histone hypoacetylation linked to memory deficits^{9HDAC2 and Memory in Alzheimer's Disease2012 · Nature · PMID 22722752Open reference}

• HDAC2 overexpression reduces synaptic plasticity

• H3K9me3 changes at AD risk gene loci

Parkinson’s disease:

• Histone modifications affect dopaminergic neuron survival

• α-synuclein interacts with histone proteins

• HDAC inhibition protective in models

ALS:

• TDP-43 pathology disrupts chromatin regulation^{10TDP-43 and Epigenetic Regulation in ALS2019 · Brain · PMID 30848275Open reference}

• Histone methylation changes at C9orf72 locus

• HDAC inhibitors in clinical trials

Chromatin Remodeling Complexes

ATP-dependent chromatin remodelers alter nucleosome positioning to regulate gene expression.

Key complexes:

• SWI/SNF: ATP-dependent remodeling, activates transcription

• NuRD: Combines remodeling with HDAC activity, represses transcription

• Polycomb Repressive Complex 1/2: H3K27 methylation, gene silencing

• INO80: DNA repair, replication

Neurodegeneration relevance:

• Mutations in chromatin remodelers cause neurodevelopmental disorders

• Altered SWI/SNF function in AD models

• NuRD complex dysregulation affects neuronal identity

Non-Coding RNAs

MicroRNAs (miRNAs)

miRNAs are ~22 nucleotide RNAs that repress translation or promote mRNA degradation.

Key miRNAs in neurodegeneration:

• miR-9: Neural development, altered in AD/PD

• miR-124: Neuronal identity, synaptic plasticity

• miR-29: Targets BACE1 in AD

• miR-153: Targets α-synuclein

Long Non-Coding RNAs (lncRNAs)

lncRNAs (>200 nt) regulate gene expression through various mechanisms.

Key lncRNAs:

• MALAT1: Synaptic plasticity, nuclear speckles

• NEAT1: Stress response, paraspeckles

• HOTAIR: Polycomb-mediated repression

• MEG3: Tumor suppressor, neuronal differentiation

Circular RNAs (circRNAs)

circRNAs are stable circular RNAs derived from back-splicing.

• Many neuronal circRNAs are highly abundant

• Function as miRNA sponges

• Change with aging and disease

Alzheimer’s Disease Mechanisms

APP Processing and Epigenetics

The amyloid precursor protein (APP) gene promoter is subject to epigenetic regulation:

• Hypomethylation of APP promoter correlates with increased Aβ production^{2Epigenetics-Based Therapeutics for Neurodegenerative Disorders2012 · Current Translational Geriatrics and Experimental Gerontology Reports · PMID 23526405Open reference}0

• Transcription factors binding affected by chromatin state

• Environmental factors (diet, stress) alter APP epigenetics

Tau Pathology and Epigenetics

Tau protein (MAPT) expression is epigenetically regulated:

• H1 haplotype risk variant affects chromatin organization

• Histone modifications at MAPT locus in tauopathy

• Therapeutic potential of HMT inhibitors

Epigenetic Clock and AD

Epigenetic age acceleration associates with:

• Increased AD risk

• Cognitive decline

• Neuropathological hallmarks

Parkinson’s Disease Mechanisms

α-Synuclein Epigenetics

The SNCA gene encoding α-synuclein is regulated by:

• Promoter methylation inversely correlates with expression^{2Epigenetics-Based Therapeutics for Neurodegenerative Disorders2012 · Current Translational Geriatrics and Experimental Gerontology Reports · PMID 23526405Open reference}1

• Histone modifications at SNCA locus

• Environmental toxins alter SNCA epigenetics

LRRK2 Regulation

LRRK2 (leucine-rich repeat kinase 2) regulatory regions show:

• Altered methylation in PD brain

• Risk variants affect transcription factor binding

• Epigenetic therapy potential

Dopaminergic Neuron Vulnerability

Epigenetic factors in dopaminergic neuron loss:

• DNA damage triggers epigenetic changes

• Aging affects neuronal epigenome

• Environmental exposures (toxins, metals)

ALS/FTD Mechanisms

C9orf72 Hexanucleotide Repeat Expansion

The most common genetic cause of ALS/FTD involves:

• Expanded GGGGCC repeats in intron 1

• Hypermethylation of the repeat region reduces toxic RNA foci formation^{2Epigenetics-Based Therapeutics for Neurodegenerative Disorders2012 · Current Translational Geriatrics and Experimental Gerontology Reports · PMID 23526405Open reference}2

• Epigenetic therapy: DNMT inhibitors being explored

TDP-43 Proteinopathy

TDP-43 (TARDBP) regulates:

• RNA splicing and stability

• Chromatin remodeling indirectly

• Loss-of-function affects neuronal transcription

Therapeutic Targeting

HDAC Inhibitors

DNMT Inhibitors

BET Inhibitors

• JQ1: Reduces tau pathology in models

• IBET151: Protective in PD models

• OTX015: ALS/FTD therapeutic potential

miRNA-Based Therapors

• miR-124 delivery: Neuroprotection in models

• Anti-miR therapy: Target toxic miRNAs

• miRNA mimics: Restore protective miRNAs

Mermaid Pathway Diagram

flowchart TD
    A["Environmental Factors"] --> B["Epigenetic Changes"]
    B --> C["1D NA Methylation"]
    B --> C["2Histone Modifications"]
    B --> C["3Chromatin Remodeling"]
    B --> C["4Non-Coding RNAs"]
    
    C["1"] --> D1["{DNMTs<br/>TET Enzymes}"]
    D["1"] --> E15mC/5hmC
    E["1"] --> F1["Gene Expression<br/>Altered"]
    
    C["2"] --> D2["{HATs<br/>HDACs}"]
    D["2"] --> E["2Acetylation"]
    E["2"] --> F2["Chromatin State<br/>Changed"]
    
    C["3"] --> D3["{SWI/SNF<br/>NuRD<br/>Polycomb}"]
    D["3"] --> E3["Nucleosome<br/>Positioning"]
    
    C["4"] --> D4["{miRNAs<br/>lncRNAs<br/>circRNAs}"]
    D["4"] --> E4["Post-Transcriptional<br/>Regulation"]
    
    F["1"] --> G["Neurodegeneration"]
    F["2"] --> G
    E["3"] --> G
    E["4"] --> G
    
    G --> H["AD Pathology"]
    G --> I["PD Pathology"]
    G --> J["ALS Pathology"]
    
    H --> K["Therapeutic Targets"]
    I --> K
    J --> K
    
    K --> L["H DAC Inhibitors"]
    K --> M["DNMT Inhibitors"]
    K --> N["BET Inhibitors"]
    K --> O["miRNA Therapies"]

Cross-Linking

• DNA Methylation

• Histone Modification

• Neurodegeneration

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis

• Epigenetic Biomarkers

• Epigenetic Therapies

See Also

• Histone Acetylation

• Histone Methylation

• Non-Coding RNA

• Gene Regulation

• Aging

Recent Research Updates (2024-2026)

• P et al. 2024: The genomic basis of childhood T-lineage acute lymphoblastic leukaemia

• J et al. 2024: Ubiquitous protein lactylation in health and diseases.

• Y et al. 2025: Epigenetics in the modern era of crop improvements.

• H et al. 2025: Functions and Mechanisms of Histone Modifications in Plants.

• GR et al. 2024: Convergence of coronary artery disease genes onto endothelial cell pro

Epigenetic Mechanisms in Neurodegeneration

DNA Methylation

DNA methylation patterns are altered in neurodegenerative diseases

• Global hypomethylation: Reduced global methylation in AD

• Gene-specific changes: Both hypermethylation and hypomethylation

• Tissue-specific effects: Different patterns in brain vs blood

• Age-related changes: Epigenetic drift with aging

Histone Modifications

Histone modification patterns in neurodegeneration- Histone acetylation: Generally reduced in disease

• Histone methylation: Complex changes in H3K4, H3K9, H3K27

• Histone phosphorylation: Early markers of pathology

• HDAC activity: Altered in AD, PD, ALS

Non-Coding RNAs

microRNAs and other ncRNAs in neurodegeneration- miR-7: Alpha-synuclein targeting in PD

• miR-29: AD-related changes

• lncRNAs: NEAT1, MALAT1 in disease

Therapeutic Implications

HDAC Inhibitors

DNA Methylation Therapy

• DNMT inhibitors: 5-azacytidine, decitabine

• Folate supplementation: Methyl donor support

• BET inhibitors: Bromodomain inhibition